MGMT and glioblastoma: Based on the results of two recent phase III clinical trials and the confirmed assay reliability, MGMT pyrosequencing fulfills the criteria for high clinical utility and is recommended for therapy planning in elderly glioblastoma patients (Box B) (Table 3) [7, 8].